Oncolytic Virotherapy for Relapsed, IDH-Mutant, Grade 3 Astrocytoma: A New Promising Approach - A Case Report

Area of Science:

• Neuro-oncology
• Viral oncology
• Cancer immunotherapy

Background:

• IDH-mutant astrocytomas are aggressive brain tumors with poor prognosis, often progressing to glioblastoma.
• Current treatments for advanced astrocytomas have limited efficacy, necessitating novel therapeutic approaches.
• Oncolytic viruses (OVs) demonstrate potential as a safe and effective treatment modality for malignant brain tumors, particularly with intra-tumoral delivery.

Observation:

• A case report details a 37-year-old female with advanced, relapsed grade 3 astrocytoma treated with intra-tumoral OV (IO-OV) therapy via an Ommaya reservoir.
• The patient received a single OV treatment cycle combined with electro-hyperthermia therapy.
• Initial treatment resulted in no evidence of disease (NED) for 9 months.

Findings:

• Intra-tumoral OV therapy led to significant clinical and radiological improvements in a patient with an otherwise incurable astrocytoma.
• The patient experienced a durable response (9 months NED) following the OV regimen.
• Disease relapse occurred after the patient contracted COVID-19, suggesting potential interactions between viral therapies and immune status.

Implications:

• Intra-tumoral OV therapy is a promising strategy for managing advanced and inoperable brain tumors.
• OV therapy should be considered as an adjunct to first-line treatments for malignant gliomas.
• Further research is warranted to explore the full therapeutic potential and optimize OV delivery methods for brain cancers.